Evaluation of Saliva Levels and Therapeutic Effects of Morinidazole, a New 5-Nitroimidazole Derivative, in Patients with Periodontal Diseases
Yongqing Wang,Yaning Mei,Meng Song,Peipei Zhang,Ningxin Jiang,Ling Meng,Ning Ou,Haibo Zhang,Lin Yin
DOI: https://doi.org/10.5897/ajpp12.1353
2014-01-01
African Journal of Pharmacy and Pharmacology
Abstract:The aim of this study was to evaluate and compare the saliva and gingival crevice fluid concentrations, as well as therapeutic effects of morinidazole (MNZ) and ornidazole (ONZ) in patients with periodontitis after intravenous (i.v.) infusion administration. 142 outpatient subjects (80 women and 62 men) were enrolled in the phase II clinical trial, and the patients were randomly assigned to receive intravenous infusions of either Ornidazole or Morinidazole, twice daily for 5 days (500 mg each time, infusion period was 50 min). A saliva was collected prior to and again after finishing the first i.v. dose at intervals of 15, 30, 45, 60, 90 min on day 1. Bacteriological studies were undertaken to determine the effectiveness of the MNZ or ONZ. Reverse phase high performance liquid chromatography (RP-HPLC) method with UV detection at 318 nm was carried out, using a mixture of KH2PO4, acetonitrile and methanol (55:15:30, v/v/v) as a mobile phase, with a flow rate of 1.0 ml/min. There was no significant difference between the MNZ and ONZ groups. The cure rate of morinidazole was found to be slightly higher than that of ONZ, just like the result of concentration in saliva, but no significant differences between the two agents were apparent. During our trial, we found that the clinical resistance of anaerobes to morinidazole was proven to be extremely rare. Key words: Periodontitis, morinidazole, ornidazole, tinidazole, saliva.